ClinicalTrials.gg
Status unknownNCT04326374Updated Mar 30, 2020

Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency

A Phase 3 interventional study of TransCon hGH and daily hGH in Growth Hormone Deficiency, Endocrine System Diseases and Hormones, sponsored by Visen Pharmaceuticals (Shanghai) Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-03-30.

Sponsored by Visen Pharmaceuticals (Shanghai) Co., Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Dwarfism, Pituitary with a site in China — 4 open to participants now, 4 under way, 2 of them phase 3. Dwarfism, Pituitary · China.

Planned enrollment
11th of 14
150 · median 306
Started
2019
the only one that year
Phase 3
3 of 15
1 open now
Registered
8th of 15
by date
Lead sponsor
1 of 15
Visen Pharmaceuticals (Shanghai) Co., Ltd.

Among the 15 studies in Dwarfism, Pituitary with a site in China, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2019, is one of 3 in phase 3, and was the 8th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

4 of the 15 studies in Dwarfism, Pituitary with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Dwarfism, Pituitary with a site in China, or all of them as a file.
02

Study summary

This study is conducted in China only. The purpose is to demonstrate the efficacy and safety of once weekly dosing of TransCon hGH, a long-acting growth hormone product, compare to once-daily dosing of human growth hormone (hGH) after 52 weeks of treatment in prepubertal children with growth hormone deficiency (GHD).

Read the detailed description

Not Provided

03

Conditions studied

  • Growth Hormone Deficiency
  • Endocrine System Diseases
  • Hormones
  • Pituitary Diseases
  • Pituitary Disease, Anterior

Keywords

  • Growth Hormone Deficiency
  • TransCon hGH
  • human growth hormone
  • hGH
04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prepubertal children with GHD in Tanner stage 1, aged of 3 years and below 17 years;
  • Impaired HT defined as at least 2.0 standard deviations (SD) below the mean height for chronological age and sex (HT SDS≤-2.0) according to the Chinese 2005 standard;
  • Diagnosis of GHD confirmed by 2 different GH stimulation tests, defined as a peak GH level of ≤10 ng/mL, determined with a validated assay. Bone age (BA) at least 6 months less than the chronological age;
  • Baseline IGF-1 level of at least 1.0 SD below the mean IGF-1 level standardized for age and sex (IGF-1 SDS ≤-1.0);
  • Written, signed of the parent(s) or legal guardian(s) of the subject and written assent of the subject (if the subject is 8 years old or above).

Exclusion criteria

Exclusion Criteria:

  • Children with a body weight below 12 kg;
  • Prior exposure to recombinant hGH or IGF-1 therapy;
  • Children with past or present intracranial tumor growth as confirmed by a sellar MRI scan (with contrast dye recommended) at Screening
  • Children born SGA (birth weight ≤10th percentile for gestational age according to the Chinese reference);
  • Children with psychosocial dwarfism;
  • Children with idiopathic short stature;
  • Other causes of short stature such as coeliac disease, hypothyroidism, or rickets;
  • History or presence of malignant disease; any evidence of present tumor growth;
  • Subjects with diabetes mellitus;
  • Closed epiphyses;
  • Major medical conditions and/or presence of to hGH treatment;
  • Participation in any other trial of an agent within 3 months prior to Screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    TransCon hGH

    TransCon hGH will be self-administered or injected by parents once weekly. The dose will be adjusted based on subject's weight. The treatment will continue 52 weeks.

    Drug: TransCon hGH

  • Active comparator
    Daily hGH

    Daily hGH will be self-administered or injected by parents once daily. The dose will be adjusted based on subject's weight. The treatment will continue 52 weeks.

    Drug: daily hGH

Interventions

  • Once weekly subcutaneous injection

    Also known as: ACP-011

  • Drugdaily hGH

    Once daily subcutaneous injection

    Also known as: somatropin (rDNA orgin) for injection

06

What researchers measure

Primary outcomes

  1. Annualized height velocity(AHV) at Week 52

    Annualized height velocity at Week 52 for weekly TransCon hGH treatment and the daily hGH treatment groups

    Time frame: 52 Weeks

Secondary outcomes

  1. AHV and the change from baseline over 52 weeks at each visit

    AHV and the change from baseline for the TransCon hGH and the daily hGH treatment group over 52 weeks at each visit

    Time frame: 52 Weeks

  2. Height SDS and the change from baseline over 52 weeks

    Height SDS and the change from baseline for the TransCon hGH and the daily hGH treatment group over 52 weeks

    Time frame: 52 weeks

  3. Serum IGF-1 and IGFBP-3 levels, and IGF-1 SDS, IGFBP-3 SDS, and the change from baseline over 52 weeks at each visit

    Serum IGF-1 and IGFBP-3 levels, and IGF-1 SDS, IGFBP-3 SDS, and the change from baseline for the TransCon hGH and the daily hGH treatment group over 52 weeks at each visit

    Time frame: 52 weeks

  4. The percentage of participants achieving IGF-1 SDS 0 to +2.0

    The normalization of IGF-1 SDS (percentage of participants achieving IGF-1 SDS 0 to +2.0 over 52 weeks for the TransCon hGH and the daily hGH treatment group

    Time frame: 52 weeks

  5. Incidence of Treatment-Emergent Adverse Events

    Time frame: 52 weeks

  6. The plasma concentration

    pharmacokinetics measure of hGH over 52 weeks in TransCon hGH group

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
  • Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,
    Wuhan, Hubei 430030, China
    Recruiting
    • Xiaoping Luo, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Apr 2022, 28 months after the start.

Of 19 phase 3 interventional studies under Dwarfism, Pituitary, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's planned 28 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2020
First posted
Mar 30, 2020
StartActual
Dec 30, 2019
Primary completionEst.
Apr 2022
CompletionEst.
Apr 2022
Last update
Mar 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04326374
Lead sponsor
Visen Pharmaceuticals (Shanghai) Co., Ltd.
Collaborators
Ascendis Pharma A/S
Responsible party
Sponsor
First posted
Mar 30, 2020
Start date
Dec 30, 2019
Primary completion
Apr 2022 (estimated)
Completion
Apr 2022 (estimated)
Last update
Mar 30, 2020

Study contacts

Lisa Chen, MD
Contact
lisa.chen@visenpharma.com
+86-02152999605
xiangling Wang, MD
Contact
xiangling.wang@visenpharma.com
Xiaoping Luo, MD
principal investigator · Tongji Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lonapegsomatropin

Start the discussion